Mirum Pharmaceuticals, Inc. reported its third quarter 2024 financial results, with total revenue reaching US$90.4 million. This represents an 89% increase compared to the same period in the previous year, driven by strong performance across its commercial medicines.
A significant milestone for the company was achieving positive operating cash flow for the first time in Q3 2024. This reflects improving financial discipline and commercial scale, providing resources for continued investment in its pipeline.
The company also highlighted the expansion of its rare disease pipeline, reinforcing its strategic focus on addressing high unmet medical needs. These results underscore Mirum's growing commercial strength and operational efficiency.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.